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Abstract 11 
Background 12 
The β2-adrenoceptor agonist dopexamine may possess anti-inflammatory actions which could reduce 13 
organ injury during endotoxaemia and laparotomy. Related effects on leucocyte-endothelial adhesion 14 
remain unclear. 15 
Methods 16 
Thirty anaesthetised Wistar rats underwent laparotomy followed by induction of endotoxaemia with 17 
lipopolysaccharide and peptidoglycan (n=24) or sham (n=6). Animals received dopexamine at 0.5 or 18 
1 µg kg-1 min-1 (D0.5 and D1), salbutamol at 0.1 µg kg-1 min-1, or saline vehicle (Sham and 19 
Control) for five hours. Intravital microscopy was performed in the ileum of the small intestine to 20 
assess leucocyteendothelial adhesion, arteriolar diameter, and functional capillary density. Global 21 
haemodynamics and biochemical indices of renal and hepatic function were also measured. 22 
Results 23 
Endotoxaemia was associated with an increase in adherent leucocytes in post-capillary venules, 24 
intestinal arteriolar vasoconstriction as well reduced arterial pressure and relative cardiac index, but 25 
functional capillary density in the muscularis was not significantly altered. Dopexamine and 26 
salbutamol administration were associated with reduced leucocyte-endothelial adhesion in post-27 
capillary venules compared to control animals. Arteriolar diameter, arterial pressure and relative 28 
cardiac index all remained similar between treated animals and controls. Functional capillary density 29 
was similar for all groups. Control group creatinine was significantly increased compared to sham 30 
and higher dose dopexamine. 31 
Conclusions 32 
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In a rodent model of laparotomy and endotoxaemia, β2-agonists were associated with reduced 33 
leucocyte-endothelial adhesion in post-capillary venules. This effect may explain some of the anti-34 
inflammatory actions of these agents. 35 
Introduction 36 
Complications following major gastrointestinal surgery have a significant impact on both short and 37 
long-term survival (1-3). Inotropic agents may have important effects on outcomes for this patient 38 
group (4).  Dopexamine is a dopamine analogue with agonist activity at β2 and dopaminergic 39 
receptors. This spectrum of activity confers vasodilator actions in addition to chronotropic and mild 40 
inotropic effects (5). Dopexamine has been used to increase cardiac output and hence tissue oxygen 41 
delivery in several trials of peri-operative haemodynamic therapy (6, 7). Other cardiovascular effects 42 
of dopexamine may include improved tissue microvascular flow and oxygenation (8). Various groups 43 
have studied the effects of dopexamine in patients following  major gastrointestinal surgery (6, 9), 44 
with promising results, although the findings of a recent large trial were inconclusive (7). 45 
Investigators have previously demonstrated potent anti-inflammatory effects of β2-adrenoceptor 46 
agonists (10-18), in particular dopexamine (19-22). However, it is unclear that β2-adrenoceptor 47 
agonism is responsible for the dopexamine-dependent reduction of leucocyte-endothelial adhesion 48 
seen in several endotoxaemia studies (19-20). The findings of previous laboratory and clinical 49 
investigations suggest dopexamine may improve tissue microvascular flow and oxygenation (8, 19, 50 
20, 23-26), and it is thought that these effects may account for much of the potential benefit of 51 
inotropic agents in the critically ill (27). However, in a previous laboratory study from our group, the 52 
haemodynamic actions of dopexamine infusion appeared to be less important than anti-inflammatory 53 
effects, including decreased plasma cytokine levels, modulation of neutrophil CD11b surface 54 
expression, and decreased pulmonary neutrophil infiltration (28).  We sought to further clarify how 55 
leucocyte-endothelial adhesion under endotoxaemia might relate to the β2-adrenoceptor agonist 56 
effects of dopexamine, and its effects on arterial pressure, cardiac output and the microcirculation. 57 
We therefore investigated the effects of dopexamine on leucocyte-endothelial adhesion within the 58 
microcirculation.  Our hypothesis was that, in a rodent model of laparotomy and endotoxaemia, 59 
dopexamine would decrease leucocyte-endothelial adhesion in intestinal post-capillary venules, 60 
through β2-adrenoceptor mediated actions. The relative contribution of β2-adrenoceptor agonism to 61 
these effects was assessed by using the β2 adrenergic agonist salbutamol as a comparator. 62 
 63 
Materials & methods 64 
Thirty male Wistar rats (240-340 g) received a standard diet and water ad libitum before the 65 
experiments. All procedures were performed with institutional approval and in accordance with the 66 
United Kingdom Home Office Guidance on the Operation of the Animals (Scientific Procedures) Act 67 
1986 under the project license PPL 70/6526. Anaesthesia was induced by intra-peritoneal injection of 68 
thiopental (120 mg kg-1) and maintained with supplementary injections administered according to 69 
regular testing for limb withdrawal to a standard stimulus. Animals were placed on a warming mat to 70 
maintain a core temperature of 37 ± 0.5 ˚C. A tracheostomy was performed, following which a short 71 
section of polyethylene tubing (internal diameter, 1.67 mm) was inserted to maintain airway patency 72 
and to facilitate spontaneous respiration. The right carotid artery was cannulated to allow blood 73 
sampling and continuous monitoring of heart rate (HR) and mean arterial pressure (MAP). The left 74 
jugular vein was cannulated for drug and fluid administration. 75 
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A 2 cm midline incision was then made through the abdominal wall to expose the peritoneum. 76 
Following laparotomy, bowel was evacuated into a moist cotton receptacle. Blunt dissection was then 77 
performed to access the abdominal vasculature. After isolation from the vena cava, a 1.5 mm 78 
ultrasonic aortic transit time flow probe (MA1.5PRB; Transonic Systems Inc., Ithaca, USA) was 79 
placed on the infra-renal aorta to measure aortic blood flow allowing calculation of relative stroke 80 
volume and relative cardiac index. The bowel was then replaced in the abdominal cavity, except for a 81 
loop of ileum just proximal to the caecum. The exposed bowel was kept moist by the application of 82 
0.9% saline drops through a pipette. The laparotomy incision above and below the exit of the 83 
terminal ileal loop from the abdomen was then closed with 5.0 vicryl to prevent excessive insensible 84 
fluid losses. The animal was maintained on a warming mat on an intravital microscopy platform and 85 
placed in the right lateral position so the ileal loop fell on to a raised section of the platform at the 86 
level of the laparotomy incision. The temperature of the raised section was thermostatically 87 
controlled at 37.5 ˚C to ensure the temperature of the exposed bowel was similar to the core 88 
temperature. This position did not interfere with the ability of the ultrasonic probes to measure aortic 89 
blood flow. Subsequently the bowel was covered with Saran wrap to prevent evaporative losses from 90 
its surface and maintain bowel microvascular integrity (29). This was followed by a 5 ml kg-1 bolus 91 
of normal saline to replace insensible fluid losses and a 15 minute stabilisation period to allow 92 
microvascular flow to stabilise. A first set of arterial blood samples was then taken (see below), the 93 
volume being replaced with an equal volume of normal saline. Animals were allowed to stabilise for 94 
15 min before being allocated randomly to one of five groups (sham, control, D0.5, D1, S). 95 
Endotoxaemia was induced over a 10 minute period in four of five groups by administering 1ml kg-1 96 
of a solution containing Escherichia coli lipopolysaccharide 0111:B4 (LPS, 1 mg ml-1) and 97 
peptidoglycan (PepG, 0.3 mg ml-1) intravenously, the sham group received 0.9% saline vehicle alone. 98 
In all groups this was followed by an infusion of 0.9% saline at 4.3 ml kg-1 h-1 though different doses 99 
of dopexamine or salbutamol were added to the D0.5, D1 and S  groups’ infusion fluid. This resulted 100 
in dopexamine infusion rates of 0.5 and 1 µg kg-1 min-1 for groups D0.5 and D1, respectively, and a 101 
salbutamol infusion rate of 0.1 µg kg-1 min-1 in group S.  This dose of salbutamol was selected as 102 
previous studies conducted in isolated guinea–pig tracheal preparations showed a ten-fold greater 103 
potency of salbutamol at the β2-adrenoceptor when compared with dopexamine (30). Intravital 104 
microscopy in the intestinal ileum was performed after 150 minutes, midway through resuscitation. It 105 
was not possible to measure global haemodynamics during this procedure. The experiment ended 106 
after five hours of resuscitation when the heart and lungs were excised. 107 
Analysis of plasma lactate, base deficit and renal and hepatic function  108 
200 µl of blood was taken at baseline and at the end of the experiment for measurement of plasma 109 
lactate concentration (Accutrend Lactate; Roche Diagnostics, Basel, Switzerland) and base deficit 110 
(Radiometer ABL77, Copenhagen, Denmark). A 1ml blood sample was also taken at the end of the 111 
experiment for measurements of urea, creatinine, alanine aminotransferase and aspartate 112 
aminotransferase by a commercial veterinary laboratory (IDEXX Laboratories Ltd, Sussex, UK). 113 
Measurement of aortic blood flow   114 
A 1.5 mm perivascular probe was applied with water-soluble sonicating gel and sited as described 115 
earlier. The probe was connected to a TS420 monitor (Transonic Systems Inc., Ithaca, USA), which 116 
was connected to a Powerlab/8SP monitoring system (AD Instruments). This allowed continuous 117 
recording of aortic blood flow and HR, and calculation of relative stroke volume and relative cardiac 118 
output (relative as infra-renal aortic blood flow is not equivalent to cardiac output). Aortic blood flow 119 
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was indexed to body weight to provide a measure of changes in relative stroke volume index (SVI) 120 
and relative cardiac index (CI). Probe calibration was performed daily according to the 121 
manufacturer’s instructions before experiments. 122 
Intravital microscopy (IVM)  123 
15 minutes before the midpoint of fluid resuscitation, 0.2mls of 0.17 g L-1 rhodamine 6G (Sigma-124 
Aldrich, Gillingham, UK) was administered intravenously to enhance the visibility of leucocytes. 125 
The animal platform was then transferred to the stage of an intravital microscope. Fluorescence 126 
microscopy was carried out using an Olympus BX61W1 microscope (Carl Zeiss Ltd.) connected to 127 
an Olympus BXUCB lamp, Uniblitz VCMD1 shutter driver and DG4-700 shutter instrument. 128 
Recordings were captured using Slidebook 5.0 software (Intelligent Imaging TTL) and saved for later 129 
offline analysis. All images were taken at x40 magnification. Leucocyte rolling and adhesion (>30 s 130 
stationary) was quantified in ileal post-capillary venules: the course of microvessels of the ileal 131 
submucosal layer was followed from collecting venules (V1) to postcapillary venules (V3), the latter 132 
being selected for analysis. Vessel length and diameter was measured and recorded. Images were 133 
recorded for a minimum of 40s. A further 0.2mls of 250 mg kg-1 ml-1 of FITC labelled bovine 134 
albumin (Sigma-Aldrich) was then administered intravenously in order to measure functional 135 
capillary density (FCD) and arteriolar diameters: the course of microvessels of the ileal submucosal 136 
layer was followed from supply arterioles (A1) to pre-capillary arterioles (A3), the latter being 137 
selected for analysis. Vessel diameter was measured and recorded. Capillaries were identified in the 138 
circular and longitudinal layers of the ileum and images were recorded for a minimum of 40s. These 139 
images were later analysed offline. The platform was then removed from the microscope stage and 140 
observations continued as before.   141 
Recordings of intravital videos were stored electronically. These files were later analysed offline 142 
using Slidebook 5.0 Reader (Intelligent Imaging Innovations (3i)) by an observer blinded to the 143 
experiment groups. Leucocyte adhesion was quantified and indexed to endothelial surface area 144 
(mm2), calculated from the diameters and lengths of the vessel segments studied and assuming 145 
cylindrical vessel geometry. Firmly adherent leucocytes were defined as those that did not move or 146 
detach from the endothelial lining within an observation period of 30s. FCD was calculated as the 147 
total length of perfused capillaries indexed to the visualised area (mm-1). 148 
Statistical analysis  149 
Data were presented as Mean (SEM) unless expressed otherwise and specifically. Kolmogorov-150 
Smirnov normality testing was performed for all groups. Normally distributed data were tested using 151 
one-way analysis of variance (ANOVA) for comparison across all groups at a given time point. Post-152 
testing was performed with Bonferroni’s tests. Occasionally when ANOVA revealed significant 153 
results but post-tests did not indicate which group was responsible, t-tests (with or without Welch’s 154 
correction depending on the variance of data) were performed to gain additional insight to the data. 155 
When data were not normally distributed in at least one group for any measurement, data were 156 
expressed as median (IQR) and the Kruskal-Wallis test was used in place of one-way ANOVA with 157 
Mann Whitney post-tests (and a Bonferroni correction). Two-tailed paired t-tests were used to 158 
compare haemodynamics at baseline with those at other time points for animals within the same 159 
group. Data were analysed with PrismGraph 4.0 (GraphPad Software, San Diego, USA). 160 
Significance was set at p<0.05. 161 
 162 
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Results 163 
Baseline characteristics and fluid management are described in Table 1 and Supplementary Table 1. 164 
There were no significant differences between groups regarding weight or volume of fluid received. 165 
Animals in the sham group required a slightly greater dose of thiopental to maintain anaesthesia 166 
(Table, Supplementary Digital Content 1). There were no baseline differences in haemodynamics, 167 
base deficit, lactate or haematocrit. In the sham group, MAP and HR did not change significantly but 168 
CI and SVI increased progressively (Table 1, Figure 1. Table, Supplementary Digital Content 1. 169 
Figure, Supplementary Digital Content 2). Compared with the sham group and baseline, controls had 170 
a significantly higher HR (p<0.05) and a significantly lower SVI and CI at 5 hours (Table 1, Figure 171 
1. Figure, Supplementary Digital Content 2). At this point control group plasma base deficit and 172 
lactate were increased compared with sham animals, the latter significantly (p<0.05) (Table 1. 173 
Figure, Supplementary Digital Content 3). Compared to shams, there were more firmly adherent 174 
leucocytes (control: 703 ± 86mm-2 vs. sham: 186 ± 68mm-2; p<0.001), and fewer rolling leucocytes 175 
in the post-capillary venules of control animals (Figure 2. Figure, Supplementary Digital Content 4). 176 
Intestinal arteriolar diameters were reduced in control animals (control: 21 ± 2µm vs sham: 39 ± 177 
3µm; p<0.01. Figure 3) although FCD in the muscularis and its component circular and longitudinal 178 
layers did not differ significantly from shams (Figure 4. Figure, Supplementary Digital Content 5). 179 
Endotoxaemia was associated with acute kidney injury but not liver dysfunction (Figure 5).  180 
Dopexamine infusion had no significant effect on any haemodynamic parameters when compared to 181 
controls, except for an increase in heart rate (Table 1, Figure 1. Table, Supplementary Digital Content 182 
1. Figure, Supplementary Digital Content 2). Similarly, dopexamine was not associated with any 183 
improvement in plasma lactate or base deficit in endotoxaemic animals (Table 1. Figure, 184 
Supplementary Digital Content 3). The major finding of this study was that at the mid-point of 185 
resuscitation dopexamine significantly reduced leucocyte adhesion in post-capillary venules when 186 
compared to controls (D0.5: 409 ± 65 mm-2, p<0.05 vs. control; D1: 361 ± 66 mm-2, p<0.01 vs. 187 
control) (Figure 2).  Furthermore dopexamine prevented the reduction in arteriolar diameter observed 188 
in control animals (Figure 3). The effects of dopexamine on FCD were complex. There were 189 
significant differences between groups in longitudinal muscle FCD (one-way ANOVA p=0.024), 190 
(Figure 4), but post-tests did not show which group was responsible for this difference. However 191 
isolated t-tests comparing each group against controls reveal that only the D1 group had a 192 
significantly reduced longitudinal FCD compared to controls (unpaired t-test with Welch’s 193 
correction, p=0.0034). Dopexamine had no effect on FCD in the circular layer of the muscularis at 194 
any dose. When comparing total muscularis FCD for all groups, differences fell outside of the limits 195 
of statistical significance (one way ANOVA p=0.058), (Figure, Supplementary Digital Content 4). 196 
Regarding organ function, renal function was improved in the D1 group compared to controls, but 197 
not the D0.5 animals (Figure 5).  198 
The infusion of salbutamol was associated with a similar pattern of haemodynamics to those 199 
observed in dopexamine treated animals (Table 1, Figure 1. Table, Supplementary Digital Content 1. 200 
Figure, Supplementary Digital Content 2), and there was also no improvement in indices of tissue 201 
perfusion (Figure, Supplementary Digital Content 3). Compared to controls, salbutamol significantly 202 
reduced leucocyte-endothelial adhesion (S: 365 ± 49 mm-2, p<0.01 vs. control) (Figure 2.). 203 
Salbutamol also appeared to prevent arteriolar vasoconstriction (Figure 3), but unlike dopexamine 204 
was not associated with any change in FCD in any layer of the muscularis (Figures 3 and 4. Figure, 205 
Supplementary Digital Content 5) and had no effect on organ injury (Figure 5). 206 
 207 
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Discussion 208 
The principal findings of this experiment were that in a rodent model of laparotomy and 209 
endotoxaemia, clinically relevant doses of dopexamine were associated with decreased leucocyte-210 
endothelial adhesion and reduced arteriolar constriction in the intestinal microvasculature. However, 211 
with the exception of an increase in heart rate, dopexamine infusion was not associated with any 212 
systemic cardiovascular effects and in particular, relative cardiac index was not improved. In the 213 
higher dose dopexamine group an amelioration of renal dysfunction as assessed by plasma creatinine 214 
was observed. Almost all these findings were replicated by the β2-adrenoceptor agonist salbutamol 215 
though salbutamol failed to improve renal function (28). 216 
  217 
This study provides evidence that dopexamine modulates the inflammatory response by reducing 218 
leucocyte-endothelial adhesion. We have previously demonstrated that in addition to reducing the 219 
pro-inflammatory cytokine response, dopexamine may also reduce the expression of leucocyte 220 
surface integrins following endotoxaemia.  We have also previously demonstrated a reduction in 221 
neutrophil infiltration in the lung of dopexamine treated endotoxaemic rats (28). It is possible that 222 
these observations are linked, such that during endotoxaemia, a dopexamine mediated reduction in 223 
surface integrin expression results in reduced leucocyte-endothelial adhesion and consequential 224 
neutrophil transmigration into the tissues. Although this experiment does not elucidate the cellular 225 
events that result in reduced leucocyte-endothelial adhesion, the similar effects of salbutamol suggest 226 
a β2-adrenoceptor mediated mechanism. In this regard it has been shown that β2- and non-β2-227 
adrenoceptor mediated elevations of cAMP reduce leucocyte adhesion (31, 32), whilst tonic activity 228 
of Protein Kinase A prevents β2-integrin activation (33). Other factors including, but not limited to, 229 
an amelioration of pro-inflammatory cytokines or drug effects on vascular endothelium may be of 230 
equal or greater relevance to these observed changes. Furthermore the relevance of reduced 231 
leucocyte-endothelial adhesion to the effect of dopexamine on organ function is also unclear because 232 
although salbutamol reduced leucocyte adhesion in post-capillary venules it did not ameliorate renal 233 
injury. 234 
 235 
The reduction in arteriolar vasoconstriction by dopexamine is consistent with the preservation of 236 
arteriolar diameters in villus arterioles and hepatic sinusoids observed in previous endotoxaemia 237 
studies with dopexamine. In those studies, dopexamine treated endotoxaemic animals had an 238 
associated preservation of total organ and microvascular blood flow compared to untreated groups 239 
(23, 26). However in our previous study we observed a reduction in ileal red cell flux during 240 
endotoxaemia (28). Assuming the same effect occurred in this study, then the similar muscularis 241 
FCD in control and sham animals suggests that any perfusion defect (assessed by FCD) must occur in 242 
the mucosa, as has been shown in other studies using intravital microscopy (34). The non-significant 243 
trend to reduction in longitudinal FCD in dopexamine treated animals may then indicate a 244 
dopexamine mediated re-distribution of blood from the outer layer of the ileum to the hypoxia prone 245 
mucosa. In this regard it is interesting to note that although salbutamol and dopexamine had similar 246 
effects on arteriolar diameters, salbutamol did not show any tendency to produce this effect on 247 
longitudinal layer FCD, did not improve renal function and showed no tendency to a reduced plasma 248 
lactate either. These differences, despite the similarity of effects otherwise, are notable and warrant 249 
further study. 250 
 251 
Previous clinical studies in major surgery including those by our own group have emphasised the role 252 
of cardiovascular optimisation in enhancing tissue oxygen delivery to reduce peri-operative 253 
morbidity (7, 8). Early studies drove clinicians to suggest this approach was beneficial as it reduced 254 
potentially harmful tissue ischaemia (35). The importance of maintaining tissue perfusion is still 255 
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supported by modern studies from peri-operative medicine where MAP is clamped at higher levels 256 
and shown to reduce the incidence of post-operative morbidity (36). This may also relate to 257 
improvements in microvascular perfusion (37). However we previously showed in surgical patients 258 
kept to a narrow MAP range that peri-operative stroke-volume guided fluid management protocols 259 
with continuous 0.5 µg kg-1 min-1 dopexamine infusion produced improvements in tissue oxygenation 260 
but without beneficial effects on markers of systemic inflammation or organ dysfunction (8). We also 261 
showed in a rodent model that dopexamine 1-2 µg kg-1 min-1 brings about potent immunomodulatory 262 
effects that are associated with improved organ function despite MAP and microvascular flow being 263 
similar to controls (28). This suggests that under surgical conditions therapeutic benefit is achievable 264 
through modulation of the host response to tissue injury and that further increases in tissue 265 
oxygenation or blood flow when perfusion is already guaranteed are redundant. In support of this, an 266 
analysis of surgical trials shows that patients with higher levels of baseline systemic inflammation are 267 
more likely to develop surgical complications (38). Similarly patients with impaired pre-operative 268 
microvascular function (who are known to have higher levels of inflammatory markers) are also 269 
more likely to suffer later complications (37, 39). Considering that previous studies have shown that 270 
surgical stress is associated with an upregulation of chemokines in the peritoneum and lungs, 271 
modulation of the host response to surgery becomes a potential explanation for the beneficial effects 272 
of dopexamine (40). However, the failure of salbutamol to improve renal function while producing a 273 
very similar spectrum of immune effects to dopexamine suggests that the mechanisms of renal 274 
protection with dopexamine are not necessarily only related to β2-adrenoceptor mediated effects on 275 
leucocyte-endothelial adhesion. 276 
 277 
Differential abilities of dopexamine and salbutamol to increase cellular cAMP may explain divergent 278 
effects on renal function (41). This might be the case if dopaminergic receptor activation by 279 
dopexamine further increased cAMP levels above that provided by β2-adrenoceptor activation (5). 280 
The importance of increasing cAMP is that regulated cell death that causes tissue injury in acute 281 
kidney injury is inhibited by cAMP mediated-pathways, as is mitochondrial biogenesis which is 282 
required for enhanced recovery from cell stress (42, 43). On the other hand β2-adrenoceptor 283 
activation has also been shown to alter systemic metabolism to increase tissue tolerance of injury 284 
(44). Therefore unexpected differential effects of the drugs at β2-adrenoceptors or in cAMP 285 
generation provide two mechanisms through which tissue damage can be minimised during the hours 286 
during and after emergency laparotomy and elective major abdominal surgery. This might also 287 
provide some explanation for the opposite findings in trials of β2-adrenoceptor agonism in acute 288 
respiratory distress syndrome (45). In those trials a week long infusion of higher doses of salbutamol 289 
were used to try and improve outcomes through a reduction in extravascular lung water but resulted 290 
in increased mortality. On the other hand in peri-operative medicine shorter-term infusions of similar 291 
agents are used to try and minimise tissue damage and organ dysfunction that can result from major 292 
surgery – trials in this setting with dopexamine have not shown any signal to increased mortality (7). 293 
  294 
Several findings of this study are consistent with previous investigations. The haemodynamic effects 295 
of endotoxaemia with or without dopexamine were replicated here and are in keeping with other 296 
studies (20, 28). Findings of intestinal arteriolar constriction are in keeping with the intense 297 
splanchnic vasoconstriction and rapid reduction of blood flow seen following endotoxaemia and 298 
shock in rodents (20, 28, 46). This study, in keeping with other studies, found arteriolar constriction 299 
could be ameliorated by dopexamine (23). Similar studies have found an increase in adherent 300 
leucocyte numbers in intestinal or mesenteric post-capillary venules that could be ameliorated by 301 
dopexamine (19, 20). A significant increase in adherent leucocytes (reduced by dopexamine) and a 302 
decrease in rolling leucocyte numbers in post-capillary venules at two and a half hours would likely 303 
have resulted in leukopenia, as found in other studies (19-23). However, some findings of the 304 
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experiment reported here, such as the failure of endotoxaemia to decrease longitudinal and circular 305 
muscularis functional capillary density are not consistent with previous studies (20). These 306 
inconsistencies are likely to be the result of differences in the endotoxin serotype, dose, method of 307 
administration and fluid loading conditions of each experiment. Our study also appears to contradict 308 
the findings of Schmidt et al regarding the role of β2-adrenoceptor agonism in leucocyte-endothelial 309 
adhesion (19). Importantly, our study design avoided the ablation of both endogenous and exogenous 310 
β2–adrenoceptor agonism that may account for differences in findings between the two studies. 311 
  312 
Our study has several strengths. The use of IVM gave qualitative and quantitative data that is 313 
unobtainable from laser Doppler flowmetry studies (20). The nature of endotoxaemia was modified, 314 
using peptidoglycan, which increases the generalizability of these findings outside of Gram negative 315 
septicaemia alone. Although the duration and nature of endotoxaemia differed from our previous 316 
study, the model behaved in a similar fashion to our previous study with respect to haemodynamics, 317 
markers of perfusion and resultant organ dysfunction. With respect to biochemical markers of tissue 318 
perfusion, it is possible that the lack of statistical significance in the D1 group where lactic acidosis 319 
and base deficit were less severe (as in our previous study) is the result of smaller sample sizes. If 320 
correct, it is notable that salbutamol neither showed any signal to an amelioration of plasma lactate 321 
nor resulted in any amelioration of renal dysfunction. This could suggest there are additional 322 
important mechanisms of action of reducing organ injury that dopexamine possesses (as discussed 323 
above). 324 
  325 
There are also limitations to the study performed. Although there were many similarities with our 326 
previous experiments, fundamental differences in design mean that it is not possible to be certain that 327 
the models behaved in an identical fashion. Secondly, although the use of IVM permitted direct 328 
visualisation of the intestinal microcirculation, expected differences in FCD were not seen between 329 
shams and controls. This may have related to the mild severity of the model (note no significant 330 
hepatic dysfunction was observed in any group), to visualising the intestinal microcirculation too 331 
early in the course of the experiment or even to the volume of fluid administered. In this regard the 332 
inability to observe changes in the microvascular bed over the entire course of the experiment was a 333 
weakness of this study. Furthermore although arteriolar diameters and muscularis FCD were 334 
observed, the inability to measure centre-line red cell velocity, mucosal FCD and mucosal inflow 335 
arteriolar diameters prevents a complete picture of the distribution of intestinal blood flow being 336 
made. Although reductions in leucocyte-endothelial adhesion were observed, it is not possible to 337 
ascertain the relative importance of this phenomenon to the reduction in organ injury seen in this or 338 
previous experiments. Derivation of the surrogates relative stroke volume and relative cardiac index 339 
from infra-renal blood flow is recognised in the literature. Nevertheless it should be noted that 340 
cardiac index may have differed between groups and the effects of different doses of vasoactive 341 
drugs may have led to differing organ blood flows above the level of measurement, none of which 342 
could have been detected by an infra-renal flow probe. Regarding the use of dopexamine and 343 
salbutamol, dose equivalence was based on previous studies in isolated tracheal preparations (30). 344 
Although haemodynamics were similar between D1 and S groups suggesting the dose selection was 345 
probably correct, it is still not possible to be certain that the effect at the β2-adrenoceptor was 346 
identical for both drugs. This may be compounded by the fact that salbutamol is a mix of two 347 
enantiomers, adding further complexity to the comparison. In this regard the use of a selective β2-348 
adrenoceptor antagonist to further disentangle the role of this drug effects will be useful in future 349 
studies. Finally, although the use of peptidoglycan increases the generalizability of these findings 350 
outside of Gram negative septicaemia, the choice of an endotoxin based model may still be criticised 351 
for lack of a true clinical correlate. 352 
 353 
   β2-agonists in endotoxaemia 
 
9 
In summary, we present experimental evidence confirming that clinically relevant doses of 354 
dopexamine reduce leucocyte-endothelial adhesion in the intestinal microvasculature and are 355 
associated with improved renal function at clinically relevant doses. As a consequence of our 356 
experiments some avenues warrant further research. The relationship between β2-adrenoceptor 357 
signalling and downstream effects on leucocyte CD11b expression, tissue tolerance mechanisms and 358 
inhibition of regulated cell death deserve further attention. The effect of dopexamine on 359 
microvascular recruitment and its relationship to cardiac index under differing fluid regimes and also 360 
the effect of dopexamine on the distribution of microvascular blood flows are two areas that also 361 
warrant further study given the disparity seen in results of our studies and others (8, 20, 23). 362 
Although peri-operative dopexamine use has been shown to be safe in randomised controlled trials 363 
and a Bayesian analysis of the OPTIMISE trial suggested a high probability of superiority of 364 
treatment efficacy, a new randomised controlled trial of peri-operative optimisation using β2-365 
adrenoceptor agonists including dopexamine is underway and will inform clinicians definitively 366 
regarding the role of peri-operative dopexamine and haemodynamic optimisation (7, 47, 48). 367 
   368 
Acknowledgements 369 
Financial support and sponsorship: This work was supported by research grants from a British 370 
Journal of Anaesthesia/Royal College of Anaesthetists Project Grant and an Intensive Care Society 371 
Young Investigator Award. NP is supported by a Kidney Research UK Post-Doctoral Fellowship 372 
(PDF4/2009). TA is supported by a jointly funded Medical Research Council and British Journal of 373 
Anaesthesia Clinical Research Training Fellowship. This work forms part of the research themes 374 
contributing to the translational portfolio of Barts and The London Cardiovascular Biomedical 375 
Research Unit, which is supported and funded by the National Institute of Health Research. RP is a 376 
National Institute for Health Research (UK) Research Professor.  377 
Author contributions statement 378 
MB carried out the in vivo studies and statistical analysis of all data. NP provided advice during in 379 
vivo studies and on study design. TA took offline measurements from intravital microscopy videos. 380 
CT  participated  in  the  design  and  coordination  of  the  study  and  provided  guidance 381 
throughout. RP conceived of the study, participated in its design and co-ordination and helped with 382 
statistical analysis. RP, CH, CT & MB together drafted the manuscript. All authors read and 383 
approved the final manuscript. 384 
Conflict of interest statement 385 
RP has received equipment loans from LiDCO Ltd and has performed consultancy work for Edwards 386 
Lifesciences and Massimo Inc. RP is a member of the associate editorial board of the British Journal 387 
of Anaesthesia. CT is CEO of William Harvey Research Limited, which is a CRO and has conducted 388 
contracted research in the area of critical care. CT is also Senior Associate Editor for the journal 389 
Shock. All other authors have no interests to declare. 390 
Contribution to the Field Statement 391 
Best practice in the haemodynamic optimisation of the patient at risk of peri-operative organ 392 
dysfunction is a clinically controversial and poorly understood area. Clinicians can select from a 393 
wide variety of strategies combining different intravenous fluids and vasoactive drugs in an attempt 394 
to prevent organ dysfunction. Exactly how and even whether these drugs and strategies can produce 395 
their purported clinical outcomes is not known and only adds to the confusion regarding best 396 
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practice. While ever-larger and costly human clinical trials are underway to try and address the 397 
question, mechanistic insight is still lacking. We here provide a second basic science study of 398 
immune, microvascular and organ preserving effects of dopexamine, the catecholamine with the best 399 
evidence for efficacy in the peri-operative setting. Through this study we further contribute to the 400 
understanding of how this drug might affect peri-operative organ dysfunction and clinical outcomes, 401 
focusing on leucocyte-endothelial interaction. This study (together with its preceding one) will add to 402 
mechanistic insight of the upcoming OPTIMISE II trial. 403 
 404 
 405 
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Tables: 586 
 587 
Table 1. Fluid administered, temporal changes in blood gas and haemodynamic parameters for 588 
each group (n=6 all groups)  589 
There were no significant differences between groups in baseline haemodynamics or volumes of  590 
fluid administered. Over the course of the experiment in shams SVI significantly increased and CI 591 
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also tended to increase, though HR and MAP did not change. In contrast HR significantly increased, 592 
while SVI and CI significantly decreased in control and dopexamine groups. MAP was significantly 593 
decreased, though this was not a consistent finding. HR also significantly increased in group S and 594 
although CI and SVI remained relatively stable MAP decreased significantly. A significantly lower 595 
lactate was seen in shams compared to controls. Data presented as mean (SEM) when all groups 596 
normally distributed, otherwise median (IQR) if ≥ 1 group not normally distributed. One-way 597 
ANOVA (post hoc Bonferroni’s test, *p<0.05, **p<0.01, ***p<0.001 vs. controls). Paired t-tests of 598 
baseline vs end experiment for mean changes (*p<0.05, **p<0.01, ***p<0.001) 599 
 600 
 Sham Control D 0.5 D1 S 
Administered 
fluid (ml kg-1) 
29.9 
(29.2 – 30.5) 
29.4 
(29.3 – 29.5) 
29.8 
(29.4 – 30.5) 
30.1 
(29.4 – 30.5) 
29.8 
(29.4 – 30.4) 
 
Baseline HR 
(bpm) 
378 
(357 – 421) 
399 
(379 – 417) 
415 
(390 – 420) 
379 
(356 – 441) 
392 
(370 – 423) 
 
Baseline MAP 
(mmHg) 
120 (7) 111 (3) 114 (5) 108 (3) 110 (6) 
 
End experiment 
HR (bpm) 
371 (8)*** 447 (12) 465 (15) 478 (9) 445 (5) 
 
End experiment 
MAP (mmHg) 
114 
(95 – 133) 
93 
(69 – 101) 
81 
(76 – 106) 
94 
(79 – 106) 
78 
(70 - 106) 
End experiment 
lactate 
(mmol L-1) 
1.7 (0.2)* 3.4 (0.5) 3.1 (0.3) 2.6 (0.4) 3.8 (0.3) 
End experiment 
base 
deficit 
(mmol L-1) 
- 0.6 (1.0) 4.5 (1.6) 2.9 (1.5) 3.3 (1.5) 6.0 (1.0) 
Mean change in 
SVI during 
experiment (ml 
kg-1) 
0.044 (0.014)* -0.036 (0.008)** 
-0.050 
(0.009)** 
-0.054 
(0.003)*** -0.020 (0.011) 
Mean change in 
CI during 
experiment 
(ml min-1 kg-1) 
15.3  
(6.2) 
-10.5  
(3.2)* 
-16.1  
(4.2)* 
-14.4  
(2.0)*** 
3.0 
(4.9) 
 601 
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 602 
Figure legends  603 
  604 
Figure 1  605 
Relative Stroke Volume Index during 5 hours of laparotomy and endotoxaemia recorded every 30 606 
minutes. Values not plotted for t180 – t210 (animals were undergoing IVM at this time and aortic 607 
flow and HR could not be measured (therefore relative SVI could not be calculated)). 608 
Relative stroke volume index in controls differed significantly for most of the experiment and until 609 
its end when compared to shams. However no significant differences in relative stroke volume index 610 
were observed between controls and groups treated with dopexamine or salbutamol at any time. The 611 
mean change in relative stroke volume index from baseline to end experiment was also significant in 612 
all groups except salbutamol treated animals (also see Table 1). Data presented as mean (SEM). One-613 
way ANOVA at each time point (Bonferroni’s post-tests, *p<0.05, **p<0.01, ***p<0.001 vs. 614 
controls).  615 
  616 
Figure 2  617 
(Left) Numbers of adherent leucocytes per square mm of endothelium in ileal post-capillary venules 618 
at 2.5 hours of laparotomy and endotoxaemia (n=6 all groups). Numbers of vessels observed per 619 
group ranged from 8-18. 620 
Sham, dopexamine and salbutamol treated groups demonstrated significantly less adhesion than 621 
controls. Data presented as mean (SEM). One-way ANOVA (Bonferroni’s post-tests, *p<0.05, 622 
**p<0.01, ***p<0.001 vs. controls)  623 
  624 
(Mid) Intestinal arteriolar diameters of the ileum at 2.5 hours of laparotomy and endotoxaemia (n=6 625 
all groups). Numbers of vessels measured per group ranged from 8-19. 626 
When compared to shams and unlike controls, ileal arteriolar diameters were not significantly 627 
reduced in dopexamine and salbutamol treated groups. Data presented as mean (SEM). One-way 628 
ANOVA (Bonferroni’s post-tests, **p<0.01 vs. shams). 629 
 630 
(Right) Intestinal functional capillary density in longitudinal layers of the ileal muscularis at 2.5 631 
hours of laparotomy and endotoxaemia (n=6 all groups). Number of images per group ranged from 632 
16-25. Groups were significantly different with respect to longitudinal FCD at 2.5 hours. Data 633 
presented as mean (SEM). One-way ANOVA p=0.024 (no groups positive in post-tests, although 634 
p<0.01 when comparing control and D1 group with unpaired t-test with Welch’s correction).  635 
  636 
Figure 3  637 
Plasma urea, creatinine, ALT and AST sampled 5 hours after laparotomy and endotoxaemia (n=6 all 638 
groups).  639 
5 hours of laparotomy and endotoxaemia caused significant acute kidney injury in controls. The 640 
degree of injury was significantly less in the D1 group. All data presented as mean (SEM). Plasma 641 
urea and creatinine: One-way ANOVA (Bonferroni’s post-tests, *p<0.05, **p<0.01, ***p<0.001 vs. 642 
controls). ALT: One-way ANOVA, p = 0.0246 (no groups positive in post-tests).  643 
 644 
